Literature DB >> 9336927

Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.

P Vandamme1, B Holmes, M Vancanneyt, T Coenye, B Hoste, R Coopman, H Revets, S Lauwers, M Gillis, K Kersters, J R Govan.   

Abstract

We performed an integrated genotypic and phenotypic analysis of 128 strains of the genera Burkholderia, Ralstonia, and Pseudomonas in order to study the taxonomic structure of Burkholderia cepacia and its relationships with other Burkholderia species. Our data show that presumed B. cepacia strains isolated from cystic fibrosis patients belong to at least five distinct genomic species, one of which was identified as Burkholderia vietnamiensis. This group of five phenotypically similar species is referred to as the B. cepacia complex. The name Burkholderia multivorans is proposed for one of these genomic species, which was formerly referred to as B. cepacia genomovar II; the remaining B. cepacia groups are referred to as genomovars I, III, and IV, pending additional differential phenotypic tests. The role and pathogenic potential of each of these taxa, particularly in view of the potentially fatal infections in cystic fibrosis patients, need further evaluation. The data presented also demonstrate that Pseudomonas glathei and Pseudomonas pyrrocinia should be reclassified as Burkholderia species.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336927     DOI: 10.1099/00207713-47-4-1188

Source DB:  PubMed          Journal:  Int J Syst Bacteriol        ISSN: 0020-7713


  171 in total

1.  Evaluation of three oligonucleotide primer sets in PCR for the identification of Burkholderia cepacia and their differentiation from Burkholderia gladioli.

Authors:  F E Clode; M E Kaufmann; H Malnick; T L Pitt
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

2.  Pseudomonas and all that.

Authors:  C A Hart; C Winstanley
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

3.  Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex.

Authors:  E Mahenthiralingam; T Coenye; J W Chung; D P Speert; J R Govan; P Taylor; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex.

Authors:  D A Henry; E Mahenthiralingam; P Vandamme; T Coenye; D P Speert
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

5.  Identification of members of the Burkholderia cepacia complex by species-specific PCR.

Authors:  P W Whitby; K B Carter; K L Hatter; J J LiPuma; T L Stull
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

Review 6.  Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

Authors:  J R Govan
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

7.  One case each of recurrent meningitis and hemoperitoneum infection with Ralstonia mannitolilytica.

Authors:  M Vaneechoutte; T De Baere; G Wauters; S Steyaert; G Claeys; D Vogelaers; G Verschraegen
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

8.  Biochemical and susceptibility tests useful for identification of nonfermenting gram-negative rods.

Authors:  Kim Laffineur; Michèle Janssens; Jacqueline Charlier; Véronique Avesani; Georges Wauters; Michel Delmée
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

9.  Molecular method to assess the diversity of Burkholderia species in environmental samples.

Authors:  Joana Falcão Salles; Francisco Adriano De Souza; Jan Dirk van Elsas
Journal:  Appl Environ Microbiol       Date:  2002-04       Impact factor: 4.792

10.  Comparative evaluation of the BD Phoenix and VITEK 2 automated instruments for identification of isolates of the Burkholderia cepacia complex.

Authors:  Sylvain Brisse; Stefania Stefani; Jan Verhoef; Alex Van Belkum; Peter Vandamme; Wil Goessens
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.